Get the Stockscreener App
110.37
0.79%
-0.88
Pre-market:
111.55
1.18
+1.07%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $110.37, with a volume of 10.17M.
It is down -0.79% in the last 24 hours and up +9.62% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$111.25
Open:
$110.04
24h Volume:
10.17M
Relative Volume:
0.86
Market Cap:
$190.98B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
35.67
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
+1.61%
1M Performance:
+9.62%
6M Performance:
-1.68%
1Y Performance:
-16.23%
1-Day Range:
$109.35
$111.41
1-Week Range:
$107.50
$112.47
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
110.37 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
331.68 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.60 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.43 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.81 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott (ABT) Stock May Be 27% Undervalued As Lingo AI Tie Up Grows - simplywall.st
Moody Lynn Lieberson & Walker LLC Has $22.52 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Prevail Innovative Wealth Advisors LLC Invests $2.83 Million in Abbott Laboratories $ABT - MarketBeat
Liberty Capital Management Inc. Invests $3.14 Million in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Has $7.06 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Holdings Lowered by Diversified Trust Co. - MarketBeat
Harmony Asset Management LLC Takes Position in Abbott Laboratories $ABT - MarketBeat
GRIMES & Co WEALTH MANAGEMENT LLC Cuts Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Unloaded Rep. Richard McCormick - MarketBeat
Abbott Business Networks, LLC shifts business model to consulting - The Laconia Daily Sun
Abbott and NACHC launch Food for Health to boos... - Pluang
Abbott (ABT) Stock Looks Reasonable On Earnings With Stronger Cash Flow - Yahoo Finance
Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare - Chain Drug Review
What Does Abbott Laboratories (ABT) Gain From This New App Controlled Pump Rollout? - Yahoo Finance
Recent Report Shows That Rep. Richard Dean Dr McCormick Sold Up to $375K Worth of Abbott Laboratories Stock - Benzinga
HM Payson & Co. Sells 15,789 Shares of Abbott Laboratories $ABT - MarketBeat
Cidel Asset Management Inc. Sells 184,792 Shares of Abbott Laboratories $ABT - MarketBeat
Fairvoy Private Wealth LLC Has $361,000 Stock Position in Abbott Laboratories $ABT - MarketBeat
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 20,339 Shares of Abbott Laboratories $ABT - MarketBeat
Fifth Third Wealth Advisors LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Asio Capital LLC Buys Shares of 37,689 Abbott Laboratories $ABT - MarketBeat
Park National Corp OH Lowers Stake in Abbott Laboratories $ABT - MarketBeat
Matrix Asset Advisors Inc. NY Invests $4.29 Million in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Revenue Breakdown – AQUISUK:ABLD - TradingView
Can Abbott Laboratories (ABT)’s Lingo Partnership With Alphabet (GOOG) Unlock a New Era of AI-Powered Health? - Yahoo Finance
Court Dismisses Amended Securities Complaint Against Abbott Laboratories - TipRanks
Abbott Opposes Consolidating 23 Spinal Cord Stimulator Injury Lawsuits - Medical Device and Diagnostic industry
Strong Buy Case for Abbott Laboratories (ABT) - Yahoo Finance
Abbott Seeks UK Ban On Chinese Rival's Glucose Monitors - Law360
Thompson Investment Management Inc. Has $1.28 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Toth Financial Advisory Corp Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Cox Capital Mgt LLC - MarketBeat
Clark & Stuart Inc Has $3.12 Million Position in Abbott Laboratories $ABT - MarketBeat
Top Abbott Executive Makes Bold Move With Fresh Insider Stock Sale - TipRanks
Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle - Investing.com
Abbott And Google Partner To Bring Lingo Glucose Data Into Google Health App - insights.citeline.com
Google and Abbott Partner to Boost Metabolic Health Insights - Healthcare Digital
What's Backing Abbott's Established Pharmaceuticals Division Growth - The Globe and Mail
Wolfe Cuts Stryker, Backs Abbott in Med-Tech Shift - TradingPedia
Abbott Laboratories (NYSE:ABT) Raised to Outperform at Wolfe Research - MarketBeat
Citigroup Adjusts Price Target on Abbott Laboratories to $125 From $112, Maintains Buy Rating - marketscreener.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More - 24/7 Wall St.
McCollum Christoferson Group LLC Sells 62,644 Shares of Abbott Laboratories $ABT - MarketBeat
V. M. Manning & CO. Inc. Acquires New Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by DAVENPORT & Co LLC - MarketBeat
Financial Solutions Advisory Group Inc. Acquires 13,623 Shares of Abbott Laboratories $ABT - MarketBeat
Rep. Mike Kelly Unloads Abbott Laboratories (NYSE:ABT) Shares - MarketBeat
Mike Kelly makes multiple trades including Abbott Laboratories and Disney stocks - Investing.com
Abbott Stock Slips As New Heart Trial Stalls - TipRanks
Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools - Yahoo Finance
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):